- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00122499
A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer
July 26, 2005 updated by: Erasmus Medical Center
This study has been designed to evaluate the efficacy and safety of a 20-mg dose of tadalafil administered "on demand" to patients with erectile dysfunction (ED) after external-beam radiotherapy (EBRT) of prostate cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Prostate cancer has become the most frequent malignancy in older men in Western countries.
Radiotherapy is a common treatment modality for early stage prostate cancer.
Because of the high incidence of post-radiation erectile dysfunction (ED), up to 72% after external-beam radiotherapy, this patient category represents a most difficult therapeutic challenge.
Oral drug therapy represents the first-line management option for patients with ED.
The results of the studies completed thus far with sildenafil show that a phosphodiesterase type 5 inhibitor is a safe and efficacious drug for the treatment of post-radiation ED.
No studies have investigated the efficacy of tadalafil in men complaining of ED after radiotherapy of prostate cancer.
Because of the extended period of effectiveness, which may last up to 36 hours after intake, tadalafil allows freedom in the choice for time of sexual activity.
Also the absence of restrictions of tadalafil intake with food or alcohol should simplify its administration.
This randomized, double-blind, placebo-controlled, cross-over study has been designed to evaluate the efficacy and safety of "on demand" dosing of 20-mg of tadalafil or placebo administered for 12 weeks to patients with ED after external-beam radiotherapy for prostate cancer.
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rotterdam, Netherlands, 3008 AE
- Erasmus MC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Heterosexual men, at least 18 years of age at Visit 1 and willing to participate in the study. If a qualifying participant has more than one female sexual partner during the study, the participant will not be excluded from the trial. However, the participant will be required to respond to the questionnaires based on the participant's sexual interactions with only one of these partners.
- Patients with histologically proven prostate cancer.
- Provide signed informed consent.
- Developed ED (defined as a consistent change in the quality of erection that adversely affects the patient's satisfaction with sexual intercourse) subsequent to EBRT for prostate cancer.
- Patients willing to make on average 1 sexual intercourse attempt every week during the study (including the 4-week run-in period without medication).
- Agree not to use any other ED treatment for at least 4 weeks before receiving the initial dose of study drug (ie, during the run-in period and during the treatment phase of the study).
- Have been treated by EBRT at least 12 months before screening and were documented to be potent before undergoing EBRT.
Exclusion Criteria:
- Patients will not be randomized if they did not make at least 1 sexual intercourse attempt during the run-in period. Also patients who are unable to appropriately complete the questionnaires will not be randomized.
- ED caused by other primary sexual disorders including premature ejaculation or ED caused by untreated endocrine disease (eg, hypopituitarism, hypothyroidism, or hypogonadism).
- History of pelvic surgery (including radical prostatectomy)
- Treatment with cancer chemotherapy or anti-androgens.
- Have a raising prostate specific antigen level or metastases at Visit 1.
- History of penile implant.
- The presence of clinically significant penile deformity in the opinion of the investigator.
- Evidence of clinically significant renal insufficiency within the last 6 months before Visit 1.
- Active symptomatic hepatobiliary disease, including patients with evidence of jaundice at Visit 1.
- Patients with chronic stable angina treated with long-acting nitrates, or patients with chronic stable angina who have required short-acting nitrates in the last 90 days, or angina occurring during sexual intercourse in the last 6 months.
- Patients having met the criteria for unstable angina (Braunwald, 1989) within 6 months before Visit 1, history of myocardial infarction or coronary artery bypass graft surgery within 90 days before Visit 1, or percutaneous coronary intervention (eg, angioplasty or stent placement) within 90 days before Visit 1.
- Any supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate >100 bpm) at rest despite medical or device therapy, or any history of spontaneous or induced sustained ventricular tachycardia (heart rate >100 bpm for ≥ 30 sec) despite medical or device therapy, or the presence of an automatic internal cardioverter-defibrillator.
- A history of sudden cardiac arrest despite medical or device therapy.
- Any evidence of congestive heart failure class 2 or above within 6 months before Visit 1 (Criteria Committee, New York Heart Association, Inc., 1964).
- A new, significant conduction defect within 90 days before Visit 1.
- Systolic blood pressure >170 or <90 mm Hg or diastolic blood pressure >100 or <50 mm Hg, or patients with a history of malignant hypertension.
- History of significant central nervous system injuries (including stroke and spinal cord injury) within the 6 months before Visit 1.
- History of HIV infection.
- Any condition that would interfere with the patient's ability to provide informed consent or comply with study instructions, would place patient at increased risk, or might confound the interpretation of the study results.
- History of drug, alcohol, or substance abuse within the 6 months before Visit 1.
- Treatment within the 30 days before Visit 1 with a drug or device that has not received regulatory approval.
- Have any condition, limitation, or disease that could, in the judgment of the investigator, preclude evaluation of response to tadalafil.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To evaluate the efficacy of 20 mg tadalafil, in comparison with placebo, in men with ED after 3-D conformal radiotherapy (3DCRT) of prostate cancer
|
Secondary Outcome Measures
Outcome Measure |
---|
Responses to the Global Assessment Questions (GAQ), and the other items of the Sexual Encounter Profile (SEP) and International Index of Erectile Function (IIEF)
|
To assess the side effects of 20 mg tadalafil in men with ED after 3DCRT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Luca Incrocci, M.D., Ph.D., Erasmus MC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Study Completion
February 1, 2005
Study Registration Dates
First Submitted
July 19, 2005
First Submitted That Met QC Criteria
July 19, 2005
First Posted (Estimate)
July 22, 2005
Study Record Updates
Last Update Posted (Estimate)
July 27, 2005
Last Update Submitted That Met QC Criteria
July 26, 2005
Last Verified
July 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Sexual Dysfunctions, Psychological
- Sexual Dysfunction, Physiological
- Prostatic Neoplasms
- Erectile Dysfunction
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Tadalafil
Other Study ID Numbers
- 232.476/2003/180
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on tadalafil
-
Institute for the Study of Urological Diseases,...RecruitingErectile DysfunctionGreece
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedBenign Prostatic HyperplasiaJapan
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownObesity and Erectile DysfuntionMexico
-
Futura Medical Developments Ltd.CompletedErectile DysfunctionUnited States, Bulgaria, Georgia, Poland
-
Saint Petersburg State University, RussiaRecruitingErectile DysfunctionRussian Federation
-
Cairo UniversityUnknownErectile DysfunctionEgypt
-
Cedars-Sinai Medical CenterCompleted
-
University of PernambucoUnknown
-
Mark FeinglosEli Lilly and Company; Duke UniversityWithdrawnNausea | Vomiting | Gastroparesis | Diabetic GastroparesisUnited States